S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

AIM ImmunoTech Stock Forecast, Price & News

+0.00 (+0.13%)
(As of 07/1/2022 03:16 PM ET)
Today's Range
50-Day Range
52-Week Range
500 shs
Average Volume
115,062 shs
Market Capitalization
$37.48 million
P/E Ratio
Dividend Yield
Price Target

AIM ImmunoTech MarketRank™ Forecast

Analyst Rating
Short Interest
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.35 out of 5 stars

Medical Sector

1370th out of 1,428 stocks

Biological Products, Except Diagnostic Industry

209th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive AIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter.

AIM ImmunoTech logo

About AIM ImmunoTech (NYSE:AIM) Stock

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.21 per share


Free Float
Market Cap
$37.48 million
Not Optionable

AIM ImmunoTech Frequently Asked Questions

How has AIM ImmunoTech's stock performed in 2022?

AIM ImmunoTech's stock was trading at $0.92 at the beginning of the year. Since then, AIM stock has decreased by 15.2% and is now trading at $0.78.
View the best growth stocks for 2022 here

When is AIM ImmunoTech's next earnings date?

AIM ImmunoTech is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for AIM ImmunoTech

How were AIM ImmunoTech's earnings last quarter?

AIM ImmunoTech Inc. (NYSE:AIM) posted its quarterly earnings results on Monday, May, 16th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 32.98% and a negative net margin of 13,933.81%.
View AIM ImmunoTech's earnings history

Who are AIM ImmunoTech's key executives?

AIM ImmunoTech's management team includes the following people:
  • Mr. Thomas K. Equels Esq., J.D., M.S., Exec. Vice Chairman, CEO & Pres (Age 69, Pay $1.29M)
  • Mr. Peter W. Rodino III, Esq., J.D., COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 71, Pay $585.45k)
  • Mr. Robert Dickey IV, M.B.A., Chief Financial Officer (Age 66)
  • Dr. David R. Strayer M.D., Chief Scientific Officer & Medical Director (Age 76)
  • Ann Marie E. Coverly, Director of Admin. & HR and Deputy Investor Relations Coordinator
  • Dr. Carol A. Smith, Chief Manufacturing Officer & Deputy Chief Scientific Officer (Age 71)
  • Jodie Pelz, Controller
  • Dr. Ralph Christopher Cavalli Ph.D., VP of QC & Manufacturing (Age 64)

What other stocks do shareholders of AIM ImmunoTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), T2 Biosystems (TTOO), Gilead Sciences (GILD), Dynavax Technologies (DVAX) and SCYNEXIS (SCYX).

What is AIM ImmunoTech's stock symbol?

AIM ImmunoTech trades on the New York Stock Exchange (NYSE) under the ticker symbol "AIM."

How do I buy shares of AIM ImmunoTech?

Shares of AIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AIM ImmunoTech's stock price today?

One share of AIM stock can currently be purchased for approximately $0.78.

How much money does AIM ImmunoTech make?

AIM ImmunoTech (NYSE:AIM) has a market capitalization of $37.48 million and generates $140,000.00 in revenue each year. The company earns $-19,130,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does AIM ImmunoTech have?

AIM ImmunoTech employs 21 workers across the globe.

How can I contact AIM ImmunoTech?

AIM ImmunoTech's mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The official website for AIM ImmunoTech is aimimmuno.com. The company can be reached via phone at (352) 448-7797, via email at ir@aimimmuno.com, or via fax at 215-988-1739.

This page (NYSE:AIM) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.